Does Semaglutide Reduce Kidney Disease Events on Top of SGLT2 Inhibitors in Patients with CKD and T2D?

Autores da FMUP

• João Pedro Melo Marques Pinho Ferreira

  Autor

Participantes de fora da FMUP

• MENDONÇA L.U.Í.S.
• NEVES J.S.

Unidades de investigação

• Cirurgia e Fisiologia

• Laboratório Associado RISE- Rede de Investigação em Saúde

  

  Investigador

  Fernando Carlos De Landér Schmitt

Abstract

[No abstract available]

Keywords

• Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; dapagliflozin; sacubitril plus valsartan; semaglutide; sodium glucose cotransporter 2 inhibitor; vericiguat; glucagon like peptide; semaglutide; adverse outcome; all cause mortality; Article; cardiovascular mortality; chronic kidney failure; drug efficacy; drug safety; estimated glomerular filtration rate; follow up; heart failure; heart failure with reduced ejection fraction; human; kidney disease; kidney function; kidney transplantation; mortality rate; non insulin dependent diabetes mellitus; renal replacement therapy; risk reduction; complication; drug therapy; non insulin dependent diabetes mellitus